Xiao Xiao

Xiao Xiao

Auto-generated profile, based on publicly available information

Xiao Xiao

Chongqing Normal University, P.R. China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in Ticks and Tick-borne Diseases
Verified
Journal Article
Open access
LFLi-Zhu Fang
Li-Zhu Fang
XXXiao Xiao
Xiao Xiao
SLSi-Cong Lei
Si-Cong Lei
JLJian-Wei Liu
Jian-Wei Liu
XYXue-Jie Yu
Xue-Jie Yu
Severe fever with thrombocytopenia syndrome virus (SFTSV), a tick-borne Bunyavirus, causes an emerging hemorrhagic fever in humans with a high fatality in Asia. The tick vectors and hosts of SFTSV are not well studied. We evaluated SFTSV transmission in laboratory reared Haemaphysalis flava ticks. RT-PCR demonstrated that after acquisition feeding in SFTSV-infected rabbits, 10 % (4/40) engorged larvae, 25% (5/20) engorged nymphs, and 50% (5/10) engorged females of H. flava became SFTSV RNA positive; after engorged larvae and nymphs molted into nymphs and adults, respectively, 12.5% (3/24) newly molted nymphs and 20% (2/10) newly molted adults were SFTSV RNA positive. Among 30 engorged females that oviposited, 10% (3/30) clutches of eggs and 3.3% (1/30) colonies of larvae were RNA positive for SFTSV. RT-PCR also showed that 6 days after being infested with SFTSV-infected ticks, 100% (3/3) rabbits infested with larvae, 100% (2/2) rabbits infested with nymphs, and 100% (2/2) rabbits infested with adult ticks became SFTSV RNA positive. In conclusion, H. flava can acquire SFTSV from infected rabbits by feeding; there is transstadial and transovarial transmission of the virus and all three stages of H. flava can transmit SFTSV to rabbits by feeding. Thus, H. flava tick is an effective vector of SFTSV and may play a role in the transmission of SFTSV in wild animals and humans.

2 November 2018 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
JSJialei Song
Jialei Song
CYChunmao Yuan
Chunmao Yuan
JYJue Yang
Jue Yang
TLTangjingjun Liu
Tangjingjun Liu
YYYao Yao
Yao Yao
YBYaacov Ben-David
Yaacov Ben-David
E26 transformation‐specific (ETS) gene family contains a common DNA‐binding domain, the ETS domain, responsible for sequence‐specific DNA recognition on target promoters. The Fli‐1 oncogene, a member of ETS gene family, plays a critical role in hematopoiesis and is overexpressed in diverse hematological malignancies. This ETS transcription factor regulates genes controlling several hallmarks of cancer and thus represents an excellent target for cancer therapy. By screening compounds isolated from the medicinal plant Dysoxylum binectariferum in China, we identified two chemically related flavagline‐like compounds including 4′‐demethoxy‐3′,4′‐methylenedioxyrocaglaol and rocaglaol that strongly inhibited Fli‐1 transactivation ability. These compounds altered expression of Fli‐1 target genes including GATA1, EKLF, SHIP1, and BCL2. Consequently, the flavagline‐like compounds suppressed proliferation, induced apoptosis, and promoted erythroid differentiation of leukemic cells in culture. These compounds also suppressed erythroleukemogenesis in vivo in a Fli‐1‐driven mouse model. Mechanistically, the compounds blocked c‐Raf‐MEK‐MAPK/ERK signaling, reduced phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), and inhibited Fli‐1 protein synthesis. Consistent with its high expression in myelomas, B‐cell lymphoma, and B chronic lymphocytic leukemia (B‐CLL), pharmacological inhibition of Fli‐1 by the flavagline‐like compounds or genetic knock‐down via shRNA significantly hindered proliferation of corresponding cell lines and patients’ samples. These results uncover a critical role of Fli‐1 in growth and survival of various hematological malignancies and point to flavagline‐like agents as lead compounds for the development of anti‐Fli‐1 drugs to treat leukemias/lymphomas overexpressing Fli‐1.

24 August 2022 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
KLKan Li
Kan Li
GLGAO Li
GAO Li
SZSen Zhou
Sen Zhou
YMYan-Rong Ma
Yan-Rong Ma
XXXiao Xiao
Xiao Xiao
TLTian-Xi Liu
Tian-Xi Liu

1 January 2023 in Brazilian Journal of Biology
Verified
Journal Article
Open access
YLY. Lan
Y. Lan
YLYanling Liang
Yanling Liang
XXX. Xiao
X. Xiao
YSYuhu Shi
Yuhu Shi
MZM. Zhu
M. Zhu
YZYu-Juan Zhang
Yu-Juan Zhang
Hypoxia is a prominent feature of head and neck cancer. However, the oxygen element characteristics of proteins and how they adapt to hypoxia microenvironments of head and neck cancer are still unknown. Human genome sequences and proteins expressed data of head and neck cancer were retrieved from pathology atlas of Human Protein Atlas project. Then compared the oxygen and carbon element contents between proteomes of head and neck cancer and normal oral mucosa-squamous epithelial cells, genome locations, pathways, and functional dissection associated with head and neck cancer were also studied. A total of 902 differentially expressed proteins were observed where the average oxygen content is higher than that of the lowly expressed proteins in head and neck cancer proteins. Further, the average oxygen content of the up regulated proteins was 2.54% higher than other. None of their coding genes were distributed on the Y chromosome. The up regulated proteins were enriched in endocytosis, apoptosis and regulation of actin cytoskeleton. The increased oxygen contents of the highly expressed and the up regulated proteins might be caused by frequent activity of cytoskeleton and adapted to the rapid growth and fast division of the head and neck cancer cells. The oxygen usage bias and key proteins may help us to understand the mechanisms behind head and neck cancer in targeted therapy, which lays a foundation for the application of stoichioproteomics in targeted therapy and provides promise for potential treatments for head and neck cancer.

3 April 2023
Verified
Other
Open access
XXXiao Xiao
Xiao Xiao
XLXiang-Ming Lao
Xiang-Ming Lao
MCMin-Min Chen
Min-Min Chen
RLRui-Xian Liu
Rui-Xian Liu
YWYuan Wei
Yuan Wei
DKDong-Ming Kuang
Dong-Ming Kuang
Supplementary Figure S1 shows association of PD-1+ and PD-1high B cells in tumor tissue with disease recurrence, plasma HBV DNA and cytokines in HCC patients, and surface markers on HCC B cells. Supplementary Figure S2 shows gating strategies for FACS, and the phenotypic and functional features of the B cell subsets. Supplementary Figure S3 expands data on factors that modulate PD-1 expression on B cells in HCC. Supplementary Figure S4 expands data on roles of Bcl-6 and STAT6 in B cell PD-1 regulation. Supplementary Figure S5 expands data on effects of PD-1 agonist on B cells. Supplementary Figure S6 expands data on effects of PD-1 triggering by PD-L1-expressing cells. Supplementary Figure S7 expands data on triggering PD-1 in B cells suppresses tumor-specific immunity. Supplementary Figure S8 shows graphical abstract for the results. Supplementary Figure S9 shows Isotype staining of FACS and immunohistochemistry (IHC) using clinical samples. Supplementary Figure S10 shows the negative expression of monocyte subset markers in tumor B cells.